Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand-Reference-Cited by-同舟云学术

Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand

Published:2014-10-21 Issue:1 Volume:11 Page:
ISSN:1743-422X
Container-title:Virology Journal
language:en
Short-container-title:Virol J

Author:

Nitatpattana Narong,Kanjanopas Kobkan,Yoksan Sutee,Satimai Wichai,Vongba Narong,Langdatsuwan Sasiporn,Nakgoi Khajornpong,Ratchakum Supot,Wauquier Nadia,Souris Marc,Auewarakul Prasert,Gonzalez Jean-Paul

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Virology

Link

https://link.springer.com/content/pdf/10.1186/1743-422X-11-183.pdf

Reference29 articles.

1. Ross RW: The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) 1956,54(2):177-191. 10.1017/S0022172400044442

2. Powers AM, Logue CH: Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 2007,88(Pt 9):2363-2377.

3. Hammon WM, Rudnick A, Sather GE: Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 1960,131(3407):1102-1103. 10.1126/science.131.3407.1102

4. Schilte C, Staikowsky F, Couderc T, Madec Y, Carpentier F, Kassab S, Albert ML, Lecuit M, Michault A: Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis 2013,7(3):e2137. 10.1371/journal.pntd.0002137

5. Chevillon C, Briant L, Renaud F, Devaux C: The Chikungunya threat: an ecological and evolutionary perspective. Microbio 2008, l6: 80-88.

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the complex interplay: immunopathology and immune evasion strategies of alphaviruses with emphasis on neurological implications;Frontiers in Cellular and Infection Microbiology;2024-08-15

2. Epidemiological inferences from serological responses to cross-reacting pathogens;2024-08-12

3. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study;The Lancet Infectious Diseases;2024-08

4. Development of RT-RPA-based point-of-care tests for epidemic arthritogenic alphaviruses;2024-05-14

5. Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials;Journal of General Virology;2024-02-29